Trials / Unknown
UnknownNCT03235167
Cytidine-phosphate-guanosine (CpG) DNA in Hepatocellular Carcinoma Combination Therapy
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Dalian University · Academic / Other
- Sex
- All
- Age
- 55 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
to observe the outcome of hepatocellular carcinoma patients under the combination treatment of transcatheter arterial chemoembolization (TACE) and CpG DNA
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CpG DNA | CpG DNA concentrate |
| PROCEDURE | transcatheter arterial chemoembolization | transcatheter arterial chemoembolization (TACE) therapy for liver cancer |
| DRUG | Placebo - Concentrate | CpG DNA vehicle |
Timeline
- Start date
- 2017-10-01
- Primary completion
- 2022-10-01
- Completion
- 2022-10-01
- First posted
- 2017-08-01
- Last updated
- 2017-09-18
Source: ClinicalTrials.gov record NCT03235167. Inclusion in this directory is not an endorsement.